Back to Search
Start Over
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation
- Source :
- "Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2018, 32 (5), pp.1070-1080. ⟨10.1038/s41375-017-0007-7⟩", Recercat: Dipósit de la Recerca de Catalunya, Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya), Malcikova, J; Tausch, E; Rossi, D; Sutton, L A; Soussi, T; Zenz, T; Kater, A P; Niemann, C U; Gonzalez, D; Davi, F; Gonzalez Diaz, M; Moreno, C; Gaidano, G; Stamatopoulos, K; Rosenquist, R; Stilgenbauer, S; Ghia, P; Pospisilova, S (2018). ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. Leukemia, 32(5):1070-1080., Leukemia, Zurich Open Repository and Archive, PubMed Central, Dipòsit Digital de Documents de la UAB, Universitat Autònoma de Barcelona, Leukemia, 32, 1070-1080. Nature Publishing Group, LEUKEMIA, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, instname, Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2018, 32 (5), pp.1070-1080. ⟨10.1038/s41375-017-0007-7⟩, Malcikova, J, Tausch, E, Rossi, D, Sutton, L A, Soussi, T, Zenz, T, Kater, A P, Niemann, C U, Gonzalez, D, Davi, F, Gonzalez Diaz, M, Moreno, C, Gaidano, G, Stamatopoulos, K, Rosenquist, R, Stilgenbauer, S, Ghia, P, Pospisilova, S & European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) — TP53 network 2018, ' ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation ' Leukemia, vol. 32, pp. 1-11 . DOI: 10.1038/s41375-017-0007-7, Malcikova, J, Tausch, E, Rossi, D, Sutton, L A, Soussi, T, Zenz, T, Kater, A P, Niemann, C U, Gonzalez, D, Davi, F, Gonzalez Diaz, M, Moreno, C, Gaidano, G, Stamatopoulos, K, Rosenquist, R, Stilgenbauer, S, Ghia, P & Pospisilova, S 2018, ' ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-Update on methodological approaches and results interpretation ', Leukemia, vol. 32, no. 5, pp. 1070-1080 . https://doi.org/10.1038/s41375-017-0007-7, Recercat. Dipósit de la Recerca de Catalunya
- Publication Year :
- 2018
-
Abstract
- Altres ajuts: Supported by the IMI 2 HARMONY JU under GA No 116026, this JU receives support from the EU's H2020 R&I program and EFPIA. Further supported by the EU Horizon 2020 projects MEDGENET 692298, AEGLE 644906, projects CEITEC 2020 (LQ1601), NCMG research infrastructure (LM2015091 funded by MEYS CR), project FNBr 65269705, FM MU ROZV/24/LF/2016, DFG (SFB1074, projects B1 and B2, and EU (FIRE CLL)), and the Swedish Cancer Society and the Swedish Research Council. Publication reflects only the authors' views and the Commission is not responsible for any use that may be made of the information it contains. In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with resistance to chemoimmunotherapy and a particularly dismal clinical outcome. On these grounds, analysis of TP53 aberrations has been incorporated into routine clinical diagnostics to improve patient stratification and optimize therapeutic decisions. The predictive implications of TP53 aberrations have increasing significance in the era of novel targeted therapies, i.e., inhibitors of B-cell receptor (BcR) signaling and anti-apoptotic BCL2 family members, owing to their efficacy in patients with TP53 defects. In this report, the TP53 Network of the European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) presents updated recommendations on the methodological approaches for TP53 mutation analysis. Moreover, it provides guidance to ensure that the analysis is performed in a timely manner for all patients requiring treatment and that the data is interpreted and reported in a consistent, standardized, and accurate way. Since next-generation sequencing technologies are gaining prominence within diagnostic laboratories, this report also offers advice and recommendations for the interpretation of TP53 mutation data generated by this methodology.
- Subjects :
- 0301 basic medicine
medicine.medical_specialty
Cancer Research
endocrine system diseases
Chronic lymphocytic leukemia
2720 Hematology
DNA Mutational Analysis
MEDLINE
[SDV.CAN]Life Sciences [q-bio]/Cancer
610 Medicine & health
Review
Review Article
Tp53 mutation
03 medical and health sciences
0302 clinical medicine
Chemoimmunotherapy
Internal medicine
[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN]
medicine
Journal Article
Humans
In patient
1306 Cancer Research
Hematologi
Intensive care medicine
neoplasms
Cancer och onkologi
Hematology
business.industry
breakpoint cluster region
High-Throughput Nucleotide Sequencing
[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology
Clinic for Hematology
medicine.disease
Genes, p53
Leukemia, Lymphocytic, Chronic, B-Cell
3. Good health
Europe
Leukemia
030104 developmental biology
Anesthesiology and Pain Medicine
Oncology
030220 oncology & carcinogenesis
Cancer and Oncology
10032 Clinic for Oncology and Hematology
2730 Oncology
business
Subjects
Details
- ISSN :
- 08876924, 65269705, and 14765551
- Database :
- OpenAIRE
- Journal :
- "Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2018, 32 (5), pp.1070-1080. ⟨10.1038/s41375-017-0007-7⟩"
- Accession number :
- edsair.doi.dedup.....1a82acc002fba73b8fc5a3c52bc50b9b
- Full Text :
- https://doi.org/10.5167/uzh-151201